State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, PR China.
State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, PR China; Faculty of Chinese Medicine, Macau University of Science and Technology, Taipa, Macau SAR, PR China; KingMed Virology Diagnostic & Translational Center, Guangzhou, Guangdong, PR China.
J Ethnopharmacol. 2020 Apr 24;252:112584. doi: 10.1016/j.jep.2020.112584. Epub 2020 Jan 21.
Liu Shen Wan (LSW), first prescribed in "Lei Yunshang Song Fen Tang Fang", traditional Chinese medicine (TCM), is used to cure influenza, tonsillitis, pharyngitis and mumps for more than one hundred years.
LSW was proved extensive pharmacological properties, for instance, anti-inflammatory, anticancer, antiviral, analgesic, antibacterial and immunomodulatory activities. Nevertheless, the mechanism of this process and the evaluation of this product is still ambiguous. Hence, the study was designed to investigate the antiviral and anti-inflammatory activities of LSW against the influenza virus in vitro and vivo.
The antiviral activities of LSW were assayed in virus-infected cells and mice. To study the antiviral effects of LSW against influenza A/PR/8/34 virus (PR8), we employed CPE inhibition assay with different concentrations of LSW at different times of infection in vitro. The mice were intranasally infected with virus to induce viral pneumonia, then treated with different doses of LSW. The death protection of the mice, the lung index, virus titer and pathological changes in the lung tissue of mice were investigated to estimate the anti-virus effect of LSW. Moreover, RT-qPCR was used to determine the mRNA expression of TNF-α, IL-1β, IL-6, and IFN-γ in the A549 cells and the supernatant of lung tissues, and the concentrations of these four cytokines in serum of mice were determined with ELISA. Western blot was used to determine the expression of TLR4, p-NF-κB p65, NF-κB p65, p-IκBα and IκBα in the A549 cells and lung tissues, which are the key targets of TLR4/NF-κB pathway. Moreover, the immunohistochemical assay was used to determine the expression of the NF-κB p65 in the mice lungs.
LSW could significantly inhibit influenza virus at different stages of viral replication (at the process of the pre-, post-, and co-virus infection) in vitro. And LSW (100 mg/kg and 50 mg/kg) could effectively increase the survival time of mice. The virus titres, lung index, pathological changes in the mice lungs also decreased. Moreover, LSW could significantly reduce the contents of IL-1β, TNF-α, IFN-γ and IL-6 in the infected cells and the infected-mice. In addition, LSW could significantly reduce the expression of TLR4, p-NF-κB p65, NF-κB p65 and p-IκBα, while increase the IκBα in the infected cells and in the lung of mice.
LSW could significantly not only inhibit virus replication and proliferation in vitro, but also ameliorate pneumonia damage in vivo. The antiviral effect was attributed to down-regulating the expression of inflammatory cytokines induced by influenza virus via regulating the activity of TLR4/NF-кB signaling pathway.
Liu Shen Wan(LSW)最初被收录在《雷允上诵芬堂方》中,是一种中药,已被用于治疗流感、扁桃体炎、咽炎和腮腺炎超过一百年。
LSW 被证明具有广泛的药理特性,例如抗炎、抗癌、抗病毒、镇痛、抗菌和免疫调节活性。然而,其作用机制和产品评估仍不明确。因此,本研究旨在研究 LSW 对流感病毒的体外和体内抗病毒和抗炎活性。
在感染细胞和小鼠中测定 LSW 的抗病毒活性。为了研究 LSW 对甲型流感病毒/PR/8/34 病毒(PR8)的抗病毒作用,我们在体外不同感染时间使用不同浓度的 LSW 进行 CPE 抑制测定。通过鼻内感染病毒诱导病毒性肺炎,然后用不同剂量的 LSW 治疗小鼠。通过测定小鼠的死亡保护率、肺指数、病毒滴度和肺组织病理变化来评估 LSW 的抗病毒效果。此外,通过 RT-qPCR 测定 A549 细胞和肺组织上清液中 TNF-α、IL-1β、IL-6 和 IFN-γ 的 mRNA 表达,通过 ELISA 测定小鼠血清中这四种细胞因子的浓度。通过 Western blot 测定 TLR4、p-NF-κB p65、NF-κB p65、p-IκBα 和 IκBα 在 A549 细胞和肺组织中的表达,这是 TLR4/NF-κB 通路的关键靶点。此外,通过免疫组织化学测定 NF-κB p65 在小鼠肺组织中的表达。
LSW 可在体外不同病毒复制阶段(在病毒感染前、后和共感染过程中)显著抑制流感病毒。LSW(100mg/kg 和 50mg/kg)可有效延长小鼠的存活时间。病毒滴度、肺指数和小鼠肺部的病理变化也减少。此外,LSW 可显著降低感染细胞和感染小鼠中 IL-1β、TNF-α、IFN-γ和 IL-6 的含量。此外,LSW 可显著降低 TLR4、p-NF-κB p65、NF-κB p65 和 p-IκBα 的表达,同时增加感染细胞和小鼠肺组织中的 IκBα。
LSW 不仅可显著抑制体外病毒复制和增殖,还可改善体内肺炎损伤。抗病毒作用归因于通过调节 TLR4/NF-кB 信号通路的活性来下调流感病毒诱导的炎症细胞因子的表达。